Atlas Trials

Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer

Clinical trial NCT07166185 · RECRUITING

Trial details

NCT number
NCT07166185
Sponsor
Blida 1 University
Status
RECRUITING
Study type
OBSERVATIONAL
Non Metastatic HER2 Positive Breast Cancer
Start date
2025-03-01
Primary completion
2025-10-01
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.